Serán Bioscience Raises $200 Million in Funding

Serán Bioscience is a contract development and manufacturing company dedicated to empowering pharmaceutical and biotechnology companies through a comprehensive suite of services. With its comprehensive services, unwavering commitment to quality, and focus on customer needs, Serán empowers pharmaceutical and biotechnology companies to achieve their full potential.

Serán Bioscience has raised $200 million from Bain Capital Life Sciences. Existing investor Vivo Capital remains a key shareholder. The new investment will help Serán significantly expand its operations, including the construction of a new large-scale manufacturing facility, which will enhance the company’s ability to offer a wide range of drug delivery and manufacturing services.

Serán Bioscience, Bend, Oregon, United States, was founded in 2016 by Dan Smithey and John Melvin. "This transaction is a significant milestone in Serán’s evolution, which will enable us to rapidly scale our clinical manufacturing capability to support launches of new medicines, as well as serve new clients seeking state-of-the-art commercial capacity,” said Dan Smithey, Co-Founder and CEO of Serán. “We are proud to have the additional support and resources of a preeminent life sciences investor in Bain Capital who shares our vision for expanding Serán’s science-based drug development capabilities to enable commercial manufacturing of complex medicines.”